Comparative Pharmacology
Head-to-head clinical analysis: GLUCOPHAGE XR versus RIOMET ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOPHAGE XR versus RIOMET ER.
GLUCOPHAGE XR vs RIOMET ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biguanide; decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Metformin XR: initial 500 mg orally once daily with evening meal, increase by 500 mg weekly; max 2000 mg per day (as XR, given once or divided twice daily).
Oral, 500 mg once daily, increase by 500 mg weekly to maximum 2000 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 17.6 hours (range 9.1–40.6 hours); clinical context: reflects slow absorption from extended-release matrix; accumulation occurs with renal impairment
Terminal elimination half-life is approximately 6.2 hours in patients with normal renal function; prolonged to up to 17.6 hours in renal impairment (eGFR <30 mL/min).
Renal: 90% unchanged; fecal: minimal (<5%)
Renal elimination of unchanged drug accounts for approximately 90% of an absorbed dose; fecal excretion is minimal (<5%).
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic